Peptides

AOD-9604: The Weight Loss Peptide That Failed Phase III (And What to Do Instead)

Medically reviewed by Medical Advisory Board Last reviewed 2026-08-08

Honest review of AOD-9604's evidence, why it failed clinical trials, and what actually works for peptide-based fat loss

AOD-9604 (Advanced Obesity Drug, GH fragment 176-191) was developed as a targeted fat-loss peptide — a fragment of growth hormone believed to carry the lipolytic activity without GH's growth-promoting effects. It showed promise in animal studies and early human trials but failed Phase III trials for obesity, and is no longer being developed as a pharmaceutical. This guide explains what it does, why it failed, and what the evidence actually supports.

AOD-9604 is one of the most heavily marketed peptides in the fat-loss space — which makes the real story about its clinical evidence all the more important to understand. Developed by Monash University and licensed to Metabolic Pharmaceuticals, it was fast-tracked into clinical trials as a potential obesity treatment. It failed. Understanding why — and what the limitations are — is essential context before considering it.

If you're researching peptides for weight loss, AOD-9604 will inevitably come up. But the gap between its marketing and its evidence is wider than almost any other peptide on the market. This guide gives you the full picture — the science, the clinical failure, and what alternatives actually have data behind them.

Want expert help with your metabolic health?

We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.

Book An Appointment With A Specialist →

What AOD-9604 Is

AOD-9604 is a synthetic peptide consisting of amino acids 176–191 of human growth hormone (the C-terminal fragment). The theory behind its development: GH has two distinct functional domains — a growth-promoting domain and a lipolytic (fat-burning) domain. By isolating just the lipolytic fragment, developers hoped to get fat loss without GH's growth-promoting and insulin-antagonizing effects — a theoretical benefit derived from the fragment's chemistry, not something confirmed in controlled human testing.

In animal studies, the results were genuinely compelling: obese mice and rats given AOD-9604 showed significant fat reduction, faster than controls, without the weight gain or insulin resistance seen with full GH. That finding is animal-derived, though, and it was never independently confirmed in the human Phase III trial before the program was discontinued — so anyone currently taking insulin or another glucose-lowering medication should talk to their prescriber before adding AOD-9604, rather than assuming the animal data on insulin applies to them. This generated substantial investor interest and a promising early development pipeline.

The Clinical Trial Results

The Phase III trial — a 24-week, double-blind, randomized controlled trial in obese patients — showed no significant difference in weight loss between AOD-9604 and placebo. The drug failed its primary endpoint.

Subsequent analysis pointed to several likely explanations:

Species translation failure: Rodent fat metabolism differs meaningfully from human fat metabolism. Compounds that work in mice frequently fail to translate to comparable human effects.
Dosing uncertainty: The effective dose in humans may differ substantially from animal-derived extrapolations.
GH receptor complexity: The lipolytic effect in humans may require more of the GH molecule's context than the isolated 176-191 fragment provides.

Following the Phase III failure, Metabolic Pharmaceuticals abandoned the obesity indication. AOD-9604 was later investigated for osteoarthritis (a different application entirely) but remains without approved indications.

AOD-9604 Dosing Protocols (Reported)

Although AOD-9604 failed Phase III and has no approved dosing, the following protocols are widely reported in the peptide community. These are not medical recommendations — they reflect what users commonly self-administer.

Parameter	Common Protocol
Dose	250–300 mcg per injection
Route	Subcutaneous injection (belly fat or thigh)
Frequency	Once daily, typically morning on empty stomach
Cycle length	8–12 weeks on, 4 weeks off
Timing	30 minutes before food (fasted state preferred to avoid insulin interference)
Alternative route	Oral troche / lozenge (lower bioavailability, convenience trade-off)

Why fasted administration? The theory is that insulin blunts lipolytic signaling. Users administer AOD-9604 first thing in the morning before eating, similar to protocols for GH secretagogues and growth hormone itself. Whether this matters for a peptide that failed to show efficacy in the first place is debatable.

Cycling rationale: Most users cycle 8–12 weeks on, 4 weeks off, based on the general peptide community convention of avoiding sustained receptor downregulation. There is no published data on optimal AOD-9604 cycling in humans.

AOD-9604 is sold lyophilized and reconstituted the same way as other injectable research peptides — see our peptide reconstitution guide for the bacteriostatic-water technique, dose-calculation formula, and storage timelines.

Current Status and What People Use It For

Despite the Phase III failure, AOD-9604 remains popular in the supplement and research chemical market. Why? Several reasons:

Marketing momentum — the "GH fragment" framing is compelling and widely repeated
Anecdotal reports of mild fat loss effects that users attribute to the compound (though these are impossible to separate from placebo, diet changes, and concurrent interventions)
The failed trial didn't prove it has zero effect — it proved the effect was not large enough to beat placebo in a controlled setting at tested doses

The honest assessment: AOD-9604 may have mild lipolytic activity in some individuals, but the evidence for meaningful fat loss is weak. People using it for weight management would likely see better results from GLP-1 peptides (semaglutide, tirzepatide) or tesamorelin (for visceral fat specifically), both of which have Phase III evidence.

AOD-9604 and GRAS Status

In 2020, the FDA granted AOD-9604 GRAS (Generally Recognized as Safe) status as a food ingredient. This is frequently cited in marketing materials as evidence of safety or legitimacy — but the context matters significantly.

What GRAS means: The compound is considered safe for use as an ingredient in food products at specified levels. Many common food additives have GRAS status (caffeine, vinegar, various amino acids). It is a safety classification for oral consumption in food, not a drug approval or endorsement of therapeutic efficacy.

What GRAS does NOT mean:

It does not mean the FDA has approved AOD-9604 as a drug or therapeutic agent
It does not validate any weight loss or fat-burning claims
It does not apply to injectable use — GRAS covers oral food ingredient use only
It does not mean the compound is effective for any medical condition

Why this matters: Some supplement companies and peptide vendors use the GRAS designation to imply FDA endorsement. The reality is that GRAS status confirms a narrow safety profile for oral food use — it says nothing about efficacy for fat loss, and it certainly doesn't cover subcutaneous injection, which is how most peptide users administer it.

AOD-9604 vs Alternatives: Side-by-Side Comparison

If fat loss is your goal, here's how AOD-9604 stacks up against alternatives that have actual clinical evidence:

	AOD-9604	Semaglutide (Wegovy)	Tesamorelin	Ipamorelin + CJC-1295
Mechanism	GH fragment — isolated lipolytic domain of growth hormone	GLP-1 receptor agonist — reduces appetite, slows gastric emptying	GHRH analog — stimulates natural GH release, targets visceral fat	GH secretagogue stack — stimulates pulsatile GH release
Evidence level	Failed Phase III for obesity; animal data only	Multiple Phase III RCTs; FDA-approved	Phase III RCTs; FDA-approved for HIV lipodystrophy	Multiple studies; widely used in functional medicine
Expected fat loss	Unproven in humans; anecdotal reports of mild effects	15–22% body weight over 68 weeks	15–25% visceral fat reduction	Modest fat loss + improved body composition over 3–6 months
Monthly cost	$30–60 (research-grade)	$300–1,300 (pharmacy) or $150–400 (compounded)	$500–800 (compounded)	$150–300 (compounded)
Access	Research chemical; some compounders	Prescription; telehealth clinics; compounders	Prescription; specialty pharmacies	Compounding pharmacies; peptide clinics
Key drawback	No proven efficacy in humans	GI side effects; muscle loss without resistance training; cost	Cost; limited to visceral fat indication	Requires daily injections; modest individual results

The comparison isn't close. GLP-1 peptides have orders of magnitude stronger evidence for peptide-based weight loss. If cost is the primary concern, the CJC-1295 + ipamorelin stack offers a better evidence-to-cost ratio than AOD-9604.

What Actually Works Instead

Goal	Better-Evidenced Alternative	Evidence
General fat loss / weight	Semaglutide (Wegovy) or tirzepatide (Zepbound)	Phase III RCTs showing 15–22% average weight loss
Visceral fat reduction	Tesamorelin	FDA-approved; Phase III data showing 15–25% VAT reduction
Body recomposition	Ipamorelin + CJC-1295	Multiple studies; widely compounded; functional medicine standard
Metabolic optimization	Sermorelin	Long safety record; FDA history; broadly available through compounders

For anyone with insulin resistance as an underlying factor in weight gain, addressing that metabolic root cause will produce better results than any peptide alone.

Frequently Asked Questions

Does AOD-9604 actually work for weight loss?

The honest answer: probably not meaningfully. The Phase III clinical trial showed no significant difference from placebo. Animal studies showed promise, but this did not translate to humans in controlled testing. Anecdotal reports of mild effects exist, but cannot be separated from placebo, concurrent dietary changes, or other compounds. For peptide-based weight loss, GLP-1 agonists (semaglutide, tirzepatide) have vastly stronger evidence.

Is AOD-9604 safe?

AOD-9604 appeared well-tolerated in clinical trials — the safety profile was not why it failed, the efficacy was. It's not scheduled as a controlled substance and no serious adverse events were attributed to it in trials. That said, it's available only as an unregulated research chemical, meaning quality control is entirely dependent on the supplier. 'Safe in trials' does not equal 'safe from an unverified vendor' — see our peptide sourcing guidance for how to check a vendor's certificate of analysis before buying. For the general symptom profile shared across injectable research peptides (injection-site irritation, mild nausea, headache, water retention), see the safety and side effects section of our peptide therapy overview.

Why do peptide vendors still sell AOD-9604 if it failed clinical trials?

Because the supplement and research chemical market isn't regulated based on clinical trial outcomes. Many compounds are sold regardless of evidence. Additionally, 'failed Phase III for obesity' doesn't mean 'completely inert' — it means it didn't produce clinically meaningful weight loss vs. placebo in the tested population at tested doses. Vendors can truthfully cite animal study data and early human pharmacokinetic data without mentioning the failed Phase III.

Is AOD-9604 legal?

In the US, AOD-9604 is sold as a research chemical — legal to purchase and possess, not approved for human therapeutic use. It's not a scheduled controlled substance. Legality varies by country — see our peptide legality guide for the country-by-country breakdown of research-chemical status; check your local regulations before purchasing.

How much does AOD-9604 cost?

Research-grade AOD-9604 typically costs $30–60 per month depending on the supplier, dose, and format (lyophilized powder for injection vs. oral troche). This makes it one of the cheapest peptides on the market — but cheap doesn't mean effective. By comparison, compounded semaglutide costs $150–400/month but has Phase III evidence for 15–22% weight loss. You generally get what you pay for in terms of evidence base.

Can AOD-9604 be combined with other peptides?

Users commonly stack AOD-9604 with other peptides, though none of these combinations have clinical evidence. Common stacks include: AOD-9604 + CJC-1295/ipamorelin (adding GH secretagogue for body recomposition), and AOD-9604 + BPC-157 (adding gut healing and anti-inflammatory effects). The rationale is additive mechanisms, but without controlled data on the combination, you're experimenting. If stacking for fat loss, replacing AOD-9604 with a GLP-1 peptide alongside the secretagogue stack would be better supported by evidence. A related question worth calling out: pairing AOD-9604 with a GLP-1 drug you're already on (semaglutide, tirzepatide) doesn't add anything evidence-based — the GLP-1 is already doing the heavy lifting for weight loss, and AOD-9604's own contribution is unproven, so you'd be adding cost and injection burden without a demonstrated benefit.

What is the difference between AOD-9604 and HGH fragment 176-191?

They are the same compound. AOD-9604 is the branded name (Advanced Obesity Drug) given by Metabolic Pharmaceuticals during clinical development. HGH fragment 176-191 is the descriptive chemical name — it refers to amino acids 176 through 191 of human growth hormone. Some vendors market them as different products at different price points, but the peptide sequence is identical. If you see 'HGH frag 176-191' sold separately from 'AOD-9604,' it's a marketing distinction, not a chemical one.

How would I know if AOD-9604 is actually working for me?

Unlike growth hormone itself, AOD-9604 has no dedicated biomarker to confirm it's active — there's no equivalent of an IGF-1 check. If you're evaluating it anyway, the only practical option is tracking body composition (not just scale weight) with a consistent method before starting and again at the end of an 8–12 week cycle. Keep in mind the Phase III trial found no measurable advantage over placebo, so any change you see is just as plausibly diet, training, or normal fluctuation as the peptide itself.

Should I talk to a specialist before choosing between AOD-9604 and an alternative?

Given the evidence gap between AOD-9604 (unproven in controlled human trials) and options like semaglutide or tesamorelin (Phase III data, FDA-approved), this is a decision worth running past a clinician rather than making from vendor marketing alone. A specialist can weigh your labs, history, and goals against what's actually been studied — book a consultation or start with the free self-assessment to see which approach fits your situation before spending on either.

Is AOD-9604 a reasonable fallback if I can't afford or access GLP-1 drugs?

No — AOD-9604 is not a reasonable substitute for GLP-1 therapy even when cost or access is the real barrier, because it lacks the Phase III evidence to say it works at all, so money spent on it is unlikely to buy any actual fat loss. If cost is the obstacle, cheaper options exist within the evidence-based lane itself — compounded semaglutide and tirzepatide run below the branded pharmacy price, and some telehealth clinics offer tiered pricing (see our Ozempic insurance and cost guide for how those tiers break down). Addressing insulin resistance directly through diet and training is another lever that can reduce how much medication you need in the first place — a cheap-but-unproven peptide is not a substitute for either approach.

Is AOD-9604 safe during pregnancy or while breastfeeding?

No human safety data exists for AOD-9604 during pregnancy or breastfeeding, so it should not be used in either situation. As an unregulated research chemical that never advanced past a failed Phase III trial, it was never evaluated for pregnancy or lactation safety, and the reproductive toxicology studies normally reviewed before a drug is approved for use during pregnancy were never generated. Anyone who is pregnant, breastfeeding, or planning a pregnancy should consult a clinician before starting any weight-management intervention, peptide or otherwise.

Topic updates

Get the weekly peptide roundup

Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results